Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Belani, Chandra P ^a   Yamamoto, Nobuyuki ^b   Bondarenko, Igor M ^c   Poltoratskiy, Artem ^d   Novello, Silvia ^e   Tang, Jie ^f   Bycott, Paul ^f   Niethammer, Andreas G ^f   Ingrosso, Antonella ^f   Kim, Sinil ^f   Scagliotti, Giorgio V ^e  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c Dnipropetrovsk State Medical Academy   (Ukraine)

^d PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^e UNIVERSITY OF TURIN   (Italy)

^f PFIZER INC   (United States)

Author keywords

Axitinib; Cisplatin; Non squamous; NSCLC; Pemetrexed

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AXITINIB; BICARBONATE; CISPLATIN; CREATININE; CYANOCOBALAMIN; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; VASCULOTROPIN A;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTHYROIDISM; INSOMNIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NON SQUAMOUS LUNG NON SMALL CELL CANCER; NON SQUAMOUS NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; IMIDAZOLES; INDAZOLES; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84900002806     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-290     Document Type: Article

References (30)

1. Cancer facts & figures 2012. Atlanta: American Cancer Society, 2012. [http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf].
2. Wang T, Nelson RA, Bogardus A, Grannis FW. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival?. Cancer 2010, 116:1518-1525. 10.1002/cncr.24871, 20108308.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, . Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98. 10.1056/NEJMoa011954, 11784875, Eastern Cooperative Oncology Group.
4. Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Song Y, Shi Y. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2013, 69:151-159. 10.1007/s00228-012-1333-3, 22729611.
5. Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol 2012, 84:47-58. 10.1016/j.critrevonc.2012.02.004, 22405734.
6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
7. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14:7272-7283. 10.1158/1078-0432.CCR-08-0652, 19010843.
8. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009, 27:3836-3841. 10.1200/JCO.2008.20.8355, 19597027.
9. Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeño J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer 2012, 107:1277-1285. 10.1038/bjc.2012.406, 3494447, 22990652.
10. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551. 10.1200/JCO.2007.15.0375, 18506025.
11. Tortorici MA, Iglesias L, Kozloff MF, Pithavala YK, Ingrosso A, Belani CP. Pharmacokinetic (PK) analysis of coadministration of axitinib and pemetrexed/cisplatin (pem/cis) in patients with non-small cell lung cancer (NSCLC) [abstract PI-69]. Clin Pharmacol Ther 2012, 91(Suppl 1):S33.
12. Cleeland CS. The M. D. Anderson Symptom Inventory User Guide [Draft]. Houston, Texas, University of Texas M. D. Anderson Cancer Center. 2010, Houston, TX: The University of Texas MD Anderson Cancer Center, [http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/MDASI_userguide.pdf].
13. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, Heeger S, Goddemeier T, O'Byrne KJ, Gatzemeier U. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer 2012, 77:376-382. 10.1016/j.lungcan.2012.03.010, 22498112.
14. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, de Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842. 10.1200/JCO.2009.26.1321, 20212250.
15. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced non-squamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012, 30:2829-2836. 10.1200/JCO.2011.41.4987, 22753922.
16. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, Vansteenkiste J, Alberola V, Strauss UP, Montegriffo E, Ong TJ, Santoro A, . NSCLC [non-small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, non-squamous non-small-cell lung cancer. J Clin Oncol 2012, 30:3084-3092. 10.1200/JCO.2011.39.7646, 22851564, NSCLC [non-small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group.
17. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13:3942-3950. 10.1158/1078-0432.CCR-07-0278, 17606728.
18. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121. 10.1152/physrev.00038.2010, 3258432, 21742796.
19. Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 2008, 7:79-89. 2390754, 18202011.
20. Hoh C, Infante JR, Burris HA, Tarazi JC, Kim S, Rosbrook B, Reid TR. Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): implications for cytotoxic chemotherapy combinations [abstract 3591]. J Clin Oncol 2011, 29(Suppl):15s.
21. Jeraj R, Liu G, Simoncic U, Vanderhoek M, Perlman S, Alberti DB, Harrison MR, Wilding G. Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI [abstract 3050]. J Clin Oncol 2010, 28(Suppl):15s.
22. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005, 7:513-520. 10.1016/j.ccr.2005.05.024, 15950901.
23. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010, 28:949-954. 10.1200/JCO.2009.25.4482, 2834434, 20085937.
24. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011, 17:3841-3849. 10.1158/1078-0432.CCR-10-2806, 21531811.
25. Mok TSK, Paz-Ares L, Wu Y-L, Novello S, Juhasz E, Aren O, Sun Y, Hirsh V, Smit EF, Lathia C, Ong TJ, Pena C. Association between tumor EGFR and KRas mutation status and clinical outcomes in NSCLC patients randomized to sorafenib plus best supportive care (BSC) or BSC alone: subanalysis of the phase III MISSION trial [abstract LBA9_PR]. Ann Oncol 2012, 23(Suppl 9):ixe1.
26. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
27. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G, . SATURN investigators Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529. 10.1016/S1470-2045(10)70112-1, 20493771, SATURN investigators.
28. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703. 10.1056/NEJMoa1006448, 3014291, 20979469.
29. Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, Ahn SH. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Cancer Biol Ther 2011, 12:458-465. 10.4161/cbt.12.5.16303, 21725210.
30. Henderson YC, Ahn SH, Kang Y, Clayman GL. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 2008, 14:4908-4914. 10.1158/1078-0432.CCR-07-1772, 18676765.